Pump thrombosis remains a feared complication for patients implanted with durable left ventricular assist devices. Optimal treatment is unknown, but consists of either pharmacologic fibrinolysis or surgical pump exchange. Fibrinolysis is less invasive, but carries a significant risk of intracerebral hemorrhage. We present four cases of LVAD pump thrombosis successfully treated with a novel protocol that consists of low-dose four-factor prothrombin complex concentrate to reverse baseline INR elevation prior to alteplase administration to minimize the risk for intracerebral hemorrhage.
MehraMRStewartGCUberPA.The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant2014; 33(1): 1–11.
2.
SaeedDMaxheraBAlbertA, et al. Conservative approaches for HeartWare ventricular assist device pump thrombosis may improve the outcome compared with immediate surgical approaches. Interact Cardiovasc Thorac Surg2016; 23(1): 90–95.
3.
OezpekerCZittermannAEnsmingerS, et al. Systemic thrombolysis versus device exchange for pump thrombosis management: a single-center experience. ASAIO J2016; 62(3): 246–251.
4.
StulakJMDunlaySMSharmaS, et al. Treatment of device thrombus in the HeartWare HVAD: success and outcomes depend significantly on the initial treatment strategy. J Heart Lung Transplant2015; 34(12): 1535–1541.
5.
LucJGYTchantchaleishviliVPhanK, et al. Medical therapy as compared to surgical device exchange for left ventricular assist device thrombosis: a systematic review and meta-analysis. ASAIO J2019; 65(4): 307–317.
6.
DangGEpperlaNMuppidiV, et al. Medical management of pump-related thrombosis in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. ASAIO J2017; 63(4): 373–385.
7.
XianYLiangLSmithEE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA2012; 307(24): 2600–2608.
8.
ChoSMHassettCRiceCJ, et al. What causes LVAD-associated ischemic stroke? Surgery, pump thrombosis, antithrombotics, and infection. ASAIO J2019; 65(8): 775–780.
9.
ChaussonNSoumahDAghasaryanM, et al. Reversal of vitamin K antagonist therapy before thrombolysis for acute ischemic stroke. Stroke2018; 49(10): 2526–2528.
10.
JaliniSJinAYTaylorSW.Reversal of warfarin anticoagulation with prothrombin complex concentrate before thrombolysis for acute stroke. Cerebrovasc Dis2012; 33(6): 597.
11.
SchwebachAAWaybrightRAJohnsonTJ.Fixed-dose four-factor prothrombin complex concentrate for vitamin K antagonist reversal: does one dose fit all?Pharmacotherapy2019; 39(5): 599–608.
12.
GrottkeORossaintRHenskensY, et al. Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model. PLoS One2013; 8(5): e64100.
13.
NajjarSSSlaughterMSPaganiFD, et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant2014; 33(1): 23–34.
